Eleven participants (5 in the progressive resistance exercise group and 6 in the aerobic exercise group) failed to attend for the full exercise program and declined selleck chemicals llc to attend for further measurement. No changes in medication were prescribed for the study participants during the intervention period. Group data for all outcomes are presented in Table 3. Individual data are presented in Table 4 (see eAddenda for Table 4). The change in HbA1c was similar in both groups. It reduced by 0.4% (SD 0.6) in the progressive resistance exercise group and by 0.3% (SD 0.9) in the aerobic exercise
group, which was not a statistically significant difference (MD –0.1%, 95% CI –0.5 to 0.3). Three of the secondary outcomes had significant between-group differences: waist circumference, peak oxygen consumption, and resting systolic blood pressure. The between-group difference in the change in waist circumference favoured the progressive resistance group (MD –1.8 cm, 95% CI –0.5 to –3.1). The between-group difference in the change in peak oxygen consumption favoured the aerobic group, improving by a mean of 5.2 ml/kg (95% CI 0.0 to 10.4) more than in the progressive resistance exercise group. The reduction in resting systolic blood pressure was significantly greater in the aerobic exercise group than in the progressive resistance exercise group (MD 9 mmHg, 95% CI 2 to 16). Comparison of the two modes of exercise
was the primary aim of the study, so the exercise regimens were matched as closely as possible for frequency, intensity, Birinapant concentration duration, and rate of progression. Because all participants in both groups who attended the exercise sessions were able to cope with the prescribed regimen, this strengthens the interpretation that between-group differences did reflect the relative
effects of the two exercise modes. Thiamine-diphosphate kinase Furthermore, although there were some dropouts, the resulting reduction in statistical power was offset by the smaller than anticipated standard deviation in HbA1c in our cohort, at 1.21%. Therefore the study had sufficient power to exclude clinically worthwhile differences between the therapies on the primary outcome. Because very few significant between-group differences were identified and the confidence intervals around the between-group differences were generally narrow, progressive resistance exercise is likely to be a similarly effective alternative to aerobic exercise. Two previous randomised trials comparing progressive resistance exercise and aerobic exercise reported better improvement in HbA1c with resistance exercise (Arora et al 2009, Cauza et al 2005). However, one trial did not describe the training programs in terms of intensity or volume (Cauza et al 2005), so it is difficult to determine the source of the between-group differences. The other trial had a small sample size (n = 10) in each arm and a wide (5% to 10%) baseline HbA1c (Arora et al 2009), so the current trial may provide more robust data.